Inhibition of cytohesin-1 by siRNA leads to reduced IGFR signaling in prostate cancer

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 7, 2011, Pages 642-646

  Zhang, Weizhong ^a   Gao, Shuohui ^a   Qin, Hanjiao ^a   Man, Yuhong ^a   Yang, Xiaohua ^a   Cao, Jian ^a   Li, Lisen ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Cytohesins; Insulin like growth factor 1 receptor; Prostate cancer; Signal transduction; Sirna interference

Indexed keywords

CYCLIN D1; CYTOHESIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR;

ARTICLE; CELL PROLIFERATION; DNA SEQUENCE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 79961073150     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011000700005     Document Type: Article

References (15)

1. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137.
2. Smith GD, Gunnell D, Holly J. Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ 2000; 321: 847-848.
3. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11: 793-814.
4. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163.
5. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-2950.
6. Djavan B, Waldert M, Seitz C, Marberger M. Insulin-like growth factors and prostate cancer. World J Urol 2001; 19: 225-233.
7. Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 2009; 16: 161-167.
8. Kolanus W. Guanine nucleotide exchange factors of the cytohesin family and their roles in signal transduction. Immunol Rev 2007; 218: 102-113.
9. Hafner M, Schmitz A, Grune I, Srivatsan SG, Paul B, Kolanus W, et al. Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance. Nature 2006; 444: 941-944.
10. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23.
11. Chen TR. Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. Cytogenet Cell Genet 1993; 62: 183-184.
12. Ohnuki Y, Marnell MM, Babcock MS, Lechner JF, Kaighn ME. Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res 1980; 40: 524-534.
13. Dey BR, Frick K, Lopaczynski W, Nissley SP, Furlanetto RW. Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10. Mol Endocrinol 1996; 10: 631-641.
14. Schmidt EV. The role of c-myc in cellular growth control. Oncogene 1999; 18: 2988-2996.
15. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007; 6: 24.